In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer
The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Abstract
The immune system can eliminate tumors, but checkpoints enable immune escape. Here, we identify immune evasion mechanisms using genome-scale in vivo CRISPR screens across cancer models treated with immune checkpoint blockade (ICB). We identify immune evasion genes and important immune inhibitory checkpoints conserved across cancers, including the non-classical major histocompatibility complex class I (MHC class I) molecule Qa-1 b/HLA-E. Surprisingly, loss of tumor interferon-γ (IFNγ) signaling sensitizes many models to immunity. The immune inhibitory effects of tumor IFN sensing are mediated through two mechanisms. First, tumor upregulation of classical MHC class I inhibits natural killer cells. Second, IFN-induced expression of Qa-1 b inhibits CD8+ T cells via the NKG2A/CD94 receptor, which is induced by ICB. Finally, we show that strong IFN signatures are associated with poor response to ICB in individuals with renal cell carcinoma or melanoma. This study reveals that IFN-mediated upregulation of classical and non-classical MHC class I inhibitory checkpoints can facilitate immune escape.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, IFN-γ has been proposed to play both stimulatory and suppressive roles in cancer, and type I IFNs are used both as an immunosuppressant to treat multiple sclerosis and as immunostimulatory adjuvant treatments for cancer (for example melanoma) and chronic viral infection (for example HCV)48–50.”
From Causal identification of single-cell experimental perturbation effects with CINEMA-OT (2023) · cites this paper as [49]
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Fast unfolding of communities in large networks
Blondel, V. D., Guillaume, J.-L., Lambiotte, R., & Lefebvre, E. (2008) · Journal of Statistical Mechanics: Theory and Experiment · doi:10.1088/1742-5468/2008/10/p10008 · Cited by 21,424
Integrated analysis of multimodal single-cell data
Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W. M., Zheng, S., Butler, A., Lee, M. J., Wilk, A. J., Darby, C., Zagar, M., et al. (2020) · doi:10.1101/2020.10.12.335331 · Cited by 15,508
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Fast, sensitive and accurate integration of single-cell data with Harmony
Korsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y., Brenner, M., Loh, P.-R., & Raychaudhuri, S. (2019) · Nature Methods · doi:10.1038/s41592-019-0619-0 · Cited by 10,488
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Near-optimal probabilistic RNA-seq quantification
Bray, N. L., Pimentel, H., Melsted, P., & Pachter, L. (2016) · Nature Biotechnology · doi:10.1038/nbt.3519 · Cited by 9,723
SCANPY: large-scale single-cell gene expression data analysis
Wolf, F. A., Angerer, P., & Theis, F. J. (2018) · Genome Biology · doi:10.1186/s13059-017-1382-0 · Cited by 8,881
Research works printed but not linked: 1
- Kossaifi, J., Panagakis, Y., Anandkumar, A. & Pantic, M. TensorLy: tensor learning in Python. J. Mach. Learn. Res. 20, 1–6 (2019).
Cited by
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 565
The present and future of the Cancer Dependency Map
Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C., & Vazquez, F. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-024-00763-x · Cited by 454
“…CRISPR–Cas9 loss-of-function screens using xenograft models of mouse solid tumours from various tissues, including the lungs, colon, pancreas, kidney and skin, to identify genes that have crucial roles in complex processes such as tumour metastasis and evasion from antitumour immunity 181–186 .”
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
Polak, R., Zhang, E. T., & Kuo, C. J. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00706-6 · Cited by 298
“Such CRISPR screens have indeed been performed in vivo to define genes essential for tumour immune evasion 194 , and such approaches could be adapted to native cancer immune organoids.”
Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
Mathew, D., Marmarelis, M. E., Foley, C., Bauml, J. M., Ye, D., Ghinnagow, R., Ngiow, S. F., Klapholz, M., Jun, S., Zhang, Z., et al. (2024) · Science · doi:10.1126/science.adf1329 · Cited by 232
“Moreover, our previous work ( 7 , 12 ) and recent genome-widegeneticscreensinmicehighlightaroleforcancer-cellIFNsignalinginICBresistance( 38 ), which is consistent with elevated levels of ISGs found in tumors from NSCLC patients that relapse after anti – PD-1 ( 2 ).”
ResultThe PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
Baumgartner, C. K., Ebrahimi-Nik, H., Iracheta-Vellve, A., Hamel, K. M., Olander, K. E., Davis, T. G. R., McGuire, K. A., Halvorsen, G. T., Avila, O. I., Patel, C. H., et al. (2023) · Nature · doi:10.1038/s41586-023-06575-7 · Cited by 186
“To corroborate this finding in another model system, we generated Jak1 -deficient KPC tumours, which lack the ability to sense IFNγ but respond to immunotherapy in vivo 27 .”
BackgroundResultSelf-citation
Metadata
- Authors
- Dubrot, J., Du, P. P., Lane-Reticker, S. K., Kessler, E. A., Muscato, A. J., Mehta, A., Freeman, S. S., Allen, P. M., Olander, K. E., Ockerman, K. M., Wolfe, C. H., Wiesmann, F., Knudsen, N. H., Tsao, H.-W., Iracheta-Vellve, A., Schneider, E. M., Rivera-Rosario, A. N., Kohnle, I. C., Pope, H. W., Ayer, A., Mishra, G., Zimmer, M. D., Kim, S. Y., Mahapatra, A., Ebrahimi-Nik, H., Frederick, D. T., Boland, G. M., Haining, W. N., Root, D. E., Doench, J. G., Hacohen, N., Yates, K. B., & Manguso, R. T.
- Affiliations
- Broad Institute (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Yates, Kathleen B.
- Manguso, Robert T.
- ORCID
- Dubrot, Juan
- Du, Peter P.
- Lane-Reticker, Sarah Kate
- Kessler, Emily A.
- Muscato, Audrey J.
- Mehta, Arnav
- Freeman, Samuel S.
- Allen, Peter M.
- Olander, Kira E.
- Ockerman, Kyle M.
- Wolfe, Clara H.
- Wiesmann, Fabius
- Knudsen, Nelson H.
- Tsao, Hsiao-Wei
- Iracheta-Vellve, Arvin
- Schneider, Emily M.
- Ayer, Austin
- Mishra, Gargi
- Zimmer, Margaret D.
- Kim, Sarah Y.
- Ebrahimi-Nik, Hakimeh
- Frederick, Dennie T.
- Boland, Genevieve M.
- Haining, W. Nicholas
- Root, David E.
- Doench, John G.
- Hacohen, Nir
- Yates, Kathleen B.
- Manguso, Robert T.
- Venue
- Nature Immunology
- Published
- 2022-09-23
- Volume
- 23
- Issue
- 10
- Pages
- 1495-1506
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W4297088172
- Cited by
- 218
- References
- 81
- Citations by year
- 2026: 50 · 2025: 62 · 2024: 62 · 2023: 39 · 2022: 5
- FWCI
- 17.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Calico Life Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Keywords
- tumor immune evasion, immune checkpoint blockade, interferon-gamma signaling, MHC class I, Qa-1b, HLA-E, natural killer cells, CD8+ T cells, immune evasion, renal cell carcinoma, melanoma, cancer immunotherapy response
- MeSH terms
- Immune Checkpoint Inhibitors, Humans, Interferon-gamma, Neoplasms, Histocompatibility Antigens Class I, CD8-Positive T-Lymphocytes, NK Cell Lectin-Like Receptor Subfamily C, Immune Evasion, Clustered Regularly Interspaced Short Palindromic Repeats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. https://app.cochat.ai/papers/10.1038/s41590-022-01315-x
- The paper
- Dubrot, J., Du, P. P., Lane-Reticker, S. K., Kessler, E. A., Muscato, A. J., Mehta, A., Freeman, S. S., Allen, P. M., Olander, K. E., Ockerman, K. M., Wolfe, C. H., Wiesmann, F., Knudsen, N. H., Tsao, H.-W., Iracheta-Vellve, A., Schneider, E. M., Rivera-Rosario, A. N., Kohnle, I. C., Pope, H. W., . . . Manguso, R. T. (2022). In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nature Immunology. https://doi.org/10.1038/s41590-022-01315-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.